跳至主導覽
跳至搜尋
跳過主要內容
慈濟大學學研人才庫 首頁
帳號申請/資料更新
連結會在新分頁中打開
English
中文
在 慈濟大學學研人才庫 搜尋內容
首頁
專家檔案
研究單位
研究成果
貴重儀器
研究計畫
獎項
活動
新聞/媒體
查看斯高帕斯 (Scopus) 概要
朱 崧肇
助理教授
腫瘤學科
電子郵件
chu1129
gms.tcu.edu
tw
h-index
h10-index
h5-index
1820
引文
19
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
539
引文
13
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
210
引文
7
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2006
2026
每年研究成果
概覽
指紋
網路
研究成果
(91)
新聞/媒體
(1)
類似的個人檔案
(6)
指紋
查看啟用 Sung-Chao Chu 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Polyethylene Terephthalate
100%
Overall Survival
99%
Fluorodeoxyglucose F 18
96%
Lung Adenocarcinoma
82%
Diseases
65%
Entropy
63%
Epidermal Growth Factor Receptor
61%
Non Small Cell Lung Cancer
56%
Flow Cytometry
53%
Fallopian Tube
51%
Progression Free Survival
49%
Carcinogenesis
47%
Lymphocyte
46%
Epithelial Cell
45%
Radiomics
45%
Neoplasm
44%
Myelodysplastic Syndrome
40%
Malignant Neoplasm
40%
Breast Cancer
38%
Primary Tumor
36%
Cancer Cell
35%
Metastatic Breast Cancer
35%
Chemotherapy
33%
Chemoradiotherapy
29%
Disease Free Survival
29%
Neutrophil
29%
Positron Emission Tomography
28%
Lymph Node Metastasis
28%
Tyrosine-Kinase Inhibitor
28%
Ovulation
28%
Biological Marker
27%
Platelet
26%
Krukenberg Tumor
25%
Xenograft
24%
Hematopoietic Cell
22%
Exosome
22%
Cohort Analysis
22%
Asbestos Exposure
22%
Bevacizumab
22%
Scatter Factor
22%
Capecitabine
22%
Neratinib
22%
Fluorine-18
22%
Serous Carcinoma
21%
Hazard Ratio
21%
Prognostic Factor
18%
Malignant Transformation
18%
Gamma Urogastrone
17%
Epidermal Growth Factor Receptor 2
17%
Positron Emission Tomography-Computed Tomography
16%
Immunology and Microbiology
Lung
68%
Overall Survival
58%
Peripheral Blood Stem Cell
51%
Fallopian Tube
42%
Neutrophil
42%
Entropy
38%
Hematopoietic Cell
38%
Granulocyte Colony-Stimulating Factor
35%
Ovulation
34%
Kinase
34%
Phosphotransferase
34%
Progression Free Survival
33%
Tyrosine
32%
Myeloid
28%
Disease Free Survival
28%
Platelet
27%
Pretreatment
27%
positron emission tomographic scan
26%
Infectious Disease
26%
Infection
26%
Dioxygen
26%
Fimbria
25%
CD34
24%
Hepatocyte Growth Factor
24%
Ankylosing Spondylitis
22%
HLA-B27
22%
Epidermal Growth Factor
22%
Cell Density
22%
Arm
22%
Lymphocyte
22%
Leukocyte Count
21%
Hematopoietic Stem Cell Transplantation
18%
Anchorage Independent Growth
17%
Cell Count
17%
Morphology
17%
Stem Cell
17%
P53
16%
Cancer Cell
15%
Double-Strand DNA Break
15%
B Cell
14%
Survival Prediction
13%
Aplastic Anemia
13%
Programmed Cell Death
13%
Lymph Node
11%
Animal Experiment
11%
Polyethylene Glycol
11%
Central Nervous System
11%
Pelvis
11%
Computer Assisted Tomography
11%
Stevens Johnson Syndrome
11%
Pharmacology, Toxicology and Pharmaceutical Science
Protein Tyrosine Kinase Inhibitor
46%
Breast Cancer
42%
Diseases
39%
Malignant Neoplasm
39%
Cisplatin
34%
Overall Survival
29%
Thrombocytopenia
25%
Metastatic Breast Cancer
25%
Bacillus Anthracis
22%
Neratinib
22%
Capecitabine
22%
Scatter Factor
22%
Vinorelbine
22%
Lung Cancer
22%
Abelson Kinase
22%
Hepatitis B Virus
22%
Granulocyte Colony Stimulating Factor
22%
Gamma Urogastrone
22%
Epidermal Growth Factor Receptor 2
22%
Progression Free Survival
20%
Chemotherapy Regimen
17%
Epidermal Growth Factor Receptor
16%
Adverse Event
15%
Lapatinib
15%
Carcinogenesis
15%
Carcinoma
15%
Malignant Transformation
14%
Lung Adenocarcinoma
14%
Febrile Neutropenia
14%
12-O-Tetradecanoylphorbol-13-Acetate
13%
Cohort Study
13%
Erythroleukemia
13%
Hepatitis B
12%
Squamous Cell Carcinoma
12%
Aromatase Inhibitor
12%
Oxaliplatin
11%
Antiestrogen
11%
Somatomedin
11%
Thalidomide
11%
Parkinson's Disease
11%
Faintness
11%
Endometrium Cancer
11%
Fluorouracil
11%
Salivary Gland Carcinoma
11%
Phototoxicity
11%
Infectious Agent
11%
Flow Cytometry
11%
Myelofibrosis
11%
Leukemia
11%
Blister
11%
